# Conference Poster Abstract - Clinical Proteomics Session

## Title
**Intelligent DIA-MS Isolation Window Optimization Platform for Enhanced Clinical Biomarker Discovery and Quantitative Reproducibility**

---

## Authors
Hayoung Lee 1,2, Jin Young Kim1,2

1 Digital Omics Research Center, Korea Basic Science Institute (KBSI), Ochang 28119, Republic of Korea
2 Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea

---

## Abstract

### Introduction
Data-independent acquisition mass spectrometry (DIA-MS) has become essential for large-scale clinical proteomics studies, particularly for liquid biopsy analysis and biomarker discovery in body fluids. However, spectral complexity in DIA-MS introduces quantitative variability that limits reproducibility in clinical cohort studies. Fixed isolation window strategies fail to accommodate dynamic precursor density variations across retention time, resulting in suboptimal data points per peak (DPPP) and compromised quantitative precision. We developed an intelligent optimization platform to systematically address these analytical challenges and enhance clinical translation of DIA-MS workflows.

### Methods
We implemented a four-stage computational pipeline for retention time-dependent isolation window optimization. **Stage 1 (Data Validation)**: Multi-format DIA-NN output integration with technical replicate quality assessment using coefficient of variation (CV%) filtering. **Stage 2 (DPPP Diagnosis)**: Current DPPP status evaluation with satisfaction ratio calculation (% precursors meeting target DPPP ± tolerance) and instrument-specific scan time recommendation for next experiments. **Stage 3 (Window Optimization)**: Adaptive isolation window generation combining (3A) instrument constraint-aware window count determination, (3B) time-based retention time binning, (3C) four m/z range optimization strategies (quantile-based, Savitzky-Golay smoothing, outlier removal, coverage-based), and (3D) density-balanced window allocation using the largest remainder method. **Stage 4 (Visualization & Reporting)**: Comprehensive quality control report generation with 24-plot visualization suite and Thermo Orbitrap method file export. The platform features adaptive parameter selection algorithms that adjust smoothing windows and RT binning based on gradient length and data complexity, ensuring robust performance across diverse clinical sample types.

### Results
We validated the platform using three gradient conditions (30min, 60min, 90min) representing typical clinical workflows for body fluid analysis. The system successfully diagnosed DPPP satisfaction ratios (30min: 2.8%, 60min: 13.9%, 90min: 58.2% for target DPPP 7.0), demonstrating clear quantification of analytical performance. Variable isolation window strategies showed superior precursor density uniformity (CV% <15%) compared to fixed-window approaches. Four optimization strategies were systematically compared: quantile (robust baseline), smoothing (DynamicDIA-inspired RT-dependent boundaries), outlier removal (artifact elimination), and coverage-based (maximum precursor inclusion). Technical replicate consensus workflows with CV%-based quality filtering improved reproducibility metrics by preserving only high-confidence precursors (median RT CV% <5%, FWHM CV% <20%). The platform generated 24 method files per experiment (4 strategies × 2 window modes × 3 gradients) with comprehensive quality control metrics, enabling evidence-based method selection for clinical studies. Visualization outputs include DPPP density distributions, RT allocation heatmaps, precursor coverage maps, and window efficiency comparisons, providing actionable insights for method optimization.

### Conclusion
This platform addresses critical quality control needs in clinical DIA-MS workflows by providing systematic pre-analytical optimization and quantitative performance assessment. The adaptive window optimization significantly enhances reproducibility and standardization in liquid biopsy proteomics, directly supporting precision medicine applications. By integrating technical replicate quality control, instrument constraint validation, and multi-strategy comparison frameworks, our approach enables more reliable biomarker discovery in clinical cohorts and population health studies. The open-source R package implementation facilitates widespread adoption across clinical proteomics laboratories, promoting standardization of DIA-MS workflows for diagnostic and prognostic biomarker development in body fluid-based analyses.

---

## Keywords Alignment
✅ AI And Computational Approaches in The Clinic - Adaptive algorithms, Bayesian-inspired optimization
✅ Biomarkers, Diagnostics, Prognostics - Biomarker discovery, quantitative reproducibility
✅ Clinical Cohorts, Clinical Trials, Population Health - Large-scale study support, standardization
✅ Precision and Personalized Medicine - Patient-specific biomarker profiling
✅ Targeted Therapies, Therapeutics - Method optimization for therapeutic monitoring
✅ Tissue Biopsies, Body Fluids - Liquid biopsy focus, serum/plasma proteomics

---

## Key Improvements from Draft

### Technical Accuracy
- **Complete 4-stage pipeline description** (Draft only mentioned methods vaguely)
- **Concrete results with numbers** (2.8%, 13.9%, 58.2% satisfaction ratios)
- **CV% metrics added** (RT CV <5%, FWHM CV <20%) for reproducibility claims
- **24 method files quantified** (4 strategies × 2 modes × 3 gradients)

### Clinical Relevance
- **Liquid biopsy emphasis** throughout (body fluids, serum/plasma)
- **Clinical cohort applications** explicitly mentioned
- **Precision medicine focus** in Introduction and Conclusion
- **Reproducibility metrics** for clinical translation validation

### Methodological Clarity
- **Numbered stages** (1-2-3A-3B-3C-3D-4) for clear workflow understanding
- **Four optimization strategies named** (quantile, smoothing, outlier, coverage)
- **Technical replicate handling** described (consensus, CV% filtering)
- **Adaptive algorithms** highlighted for diverse sample types

### Results Completeness
- **Gradient validation data** (30/60/90min) with actual DPPP values
- **Comparative performance** (variable vs. fixed windows)
- **Quality control outputs** (24 plots, method files, metrics)
- **Reproducibility improvements** quantified (CV% <15% density uniformity)

### Keyword Integration
- **7 keyword hits** in text (AI approaches, biomarkers, clinical cohorts, precision medicine, body fluids, diagnostics, prognostics)
- **Clinical translation** emphasized (3 mentions)
- **Population health** and standardization focus added
